JP2020516617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516617A5 JP2020516617A5 JP2019554986A JP2019554986A JP2020516617A5 JP 2020516617 A5 JP2020516617 A5 JP 2020516617A5 JP 2019554986 A JP2019554986 A JP 2019554986A JP 2019554986 A JP2019554986 A JP 2019554986A JP 2020516617 A5 JP2020516617 A5 JP 2020516617A5
- Authority
- JP
- Japan
- Prior art keywords
- pgdh inhibitor
- substituted
- pgdh
- aryl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heteroaryl aryl Chemical group 0.000 claims 18
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims 15
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 229910019142 PO4 Inorganic materials 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229940127089 cytotoxic agent Drugs 0.000 claims 4
- 235000021317 phosphate Nutrition 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000005277 alkyl imino group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000005133 alkynyloxy group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims 2
- 125000004467 aryl imino group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 231100000457 cardiotoxic Toxicity 0.000 claims 2
- 230000001451 cardiotoxic effect Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 claims 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 claims 1
- 229960004176 aclarubicin Drugs 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 210000004413 cardiac myocyte Anatomy 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 229960001221 pirarubicin Drugs 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 150000003457 sulfones Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 229960000653 valrubicin Drugs 0.000 claims 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 229960000641 zorubicin Drugs 0.000 claims 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022119729A JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762483177P | 2017-04-07 | 2017-04-07 | |
| US62/483,177 | 2017-04-07 | ||
| PCT/US2018/026739 WO2018187810A1 (en) | 2017-04-07 | 2018-04-09 | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119729A Division JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020516617A JP2020516617A (ja) | 2020-06-11 |
| JP2020516617A5 true JP2020516617A5 (https=) | 2020-07-30 |
| JP7178360B2 JP7178360B2 (ja) | 2022-11-25 |
Family
ID=63712743
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554986A Active JP7178360B2 (ja) | 2017-04-07 | 2018-04-09 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
| JP2022119729A Pending JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119729A Pending JP2022141930A (ja) | 2017-04-07 | 2022-07-27 | 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11426420B2 (https=) |
| EP (1) | EP3606520A4 (https=) |
| JP (2) | JP7178360B2 (https=) |
| CN (1) | CN110891568A (https=) |
| AU (1) | AU2018249956B2 (https=) |
| CA (1) | CA3059255A1 (https=) |
| WO (1) | WO2018187810A1 (https=) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
| US12616681B2 (en) | 2022-08-22 | 2026-05-05 | Case Western Reserve University | Compositions and methods for treating renal injury |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| CN107921025A (zh) | 2015-03-08 | 2018-04-17 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| WO2018187810A1 (en) | 2017-04-07 | 2018-10-11 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
| KR20220146458A (ko) | 2020-01-23 | 2022-11-01 | 마이오포르테 테라퓨틱스 인코포레이티드 | Pgdh 억제제 및 그의 제조 및 사용 방법 |
| AU2021275122A1 (en) | 2020-05-20 | 2022-12-15 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| EP4164638A4 (en) * | 2020-06-11 | 2024-06-19 | The Board of Trustees of the Leland Stanford Junior University | REJUVENATION OF AGED TISSUES AND ORGANS BY INHIBITION OF THE DEGRADING ENZYME PGE2, 15-PGDH |
| WO2022032230A1 (en) * | 2020-08-07 | 2022-02-10 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating neurodegeneration |
| WO2025170936A1 (en) * | 2024-02-05 | 2025-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and methods for treating cardiac dysfunction |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR80916B (en) | 1983-11-14 | 1985-03-12 | Dow Chemical Co | Method of preparing 1,2,4-triazolo (1,5-a)-pyrimidine-2-sulfonyl chlorides |
| ES2069050T3 (es) | 1989-01-11 | 1995-05-01 | Ciba Geigy Ag | Antidotos para mejorar la tolerancia de las plantas de cultivo frente a sustancias activas agroquimicas. |
| EP0434624B1 (de) | 1989-12-22 | 1995-02-08 | Ciba-Geigy Ag | Triazolylsulfonamide |
| SE9303444D0 (sv) | 1993-10-20 | 1993-10-20 | Kabi Pharmacia Ab | New use of prostaglandins |
| US6080772A (en) | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
| EP1021179B1 (en) | 1997-02-04 | 2004-05-12 | Murray A. Johnstone | Method of enhancing hair growth |
| US20030096823A1 (en) * | 2001-11-16 | 2003-05-22 | Beryl Asp | Method for the treatment of cardiotoxicity induced by antitumor compounds |
| EP1558252B1 (en) | 2002-08-02 | 2007-10-10 | Merck & Co., Inc. | Substituted furo [2,3-b]pyridine derivatives |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| WO2004089416A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
| JP2006522744A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
| US7189724B2 (en) | 2003-04-15 | 2007-03-13 | Valeant Research And Development | Quinoxaline derivatives having antiviral activity |
| NZ546044A (en) | 2003-08-29 | 2009-09-25 | Vernalis Cambridge Ltd | Pyrimidothiophene compounds |
| WO2006019832A1 (en) | 2004-07-22 | 2006-02-23 | Ptc Therapeutics, Inc. | Thienopyridines for treating hepatitis c |
| CN101107251A (zh) | 2005-01-19 | 2008-01-16 | 默克公司 | 用于治疗或预防糖尿病的作为二肽基肽酶-ⅳ抑制剂的双环嘧啶类 |
| ATE479690T1 (de) | 2005-12-20 | 2010-09-15 | Richter Gedeon Nyrt | Thienoä2,3-büpyridin derivate |
| WO2009073460A2 (en) | 2007-12-03 | 2009-06-11 | Bausch & Lomb Incorporated | Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US9216983B2 (en) | 2007-12-21 | 2015-12-22 | Board Of Regents, University Of Texas System | Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity |
| KR101172638B1 (ko) * | 2008-12-30 | 2012-08-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| WO2011041304A2 (en) | 2009-09-29 | 2011-04-07 | Board Of Regents, University Of Texas System | Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase |
| GB201107197D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Compounds |
| US20130078632A1 (en) | 2011-09-23 | 2013-03-28 | Academisch Medisch Centrum | Materials and methods for prognosis of progression of barrett's esophagus |
| AU2013202373B2 (en) | 2012-01-25 | 2016-04-14 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| EP3095056B1 (en) | 2013-11-19 | 2021-01-20 | Zhou, Zhongren | Combined cytology and molecular testing for early detection of esophageal adenocarcinoma |
| CN106458934B (zh) | 2014-04-18 | 2019-08-16 | 米伦纽姆医药公司 | 喹喔啉化合物及其用途 |
| EP3179995B1 (en) | 2014-08-12 | 2018-11-07 | University of Pécs (Pécsi Tudományegyetem) | Methods and materials for reducing ischemia-reperfusion injury |
| CN107921025A (zh) | 2015-03-08 | 2018-04-17 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| AU2016248080A1 (en) | 2015-04-14 | 2017-11-02 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| JP2019513010A (ja) * | 2016-03-04 | 2019-05-23 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | プロスタグランジンｅ２を用いる、筋再生のための組成物および方法 |
| US20190275014A1 (en) | 2016-07-18 | 2019-09-12 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting cell death |
| EP3548035A4 (en) | 2016-11-30 | 2020-07-22 | Case Western Reserve University | COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES |
| JP2020514323A (ja) | 2017-02-06 | 2020-05-21 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物と方法 |
| WO2018187810A1 (en) | 2017-04-07 | 2018-10-11 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for treating coronary disorders |
| US20210317132A1 (en) | 2017-05-26 | 2021-10-14 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| KR102921276B1 (ko) * | 2018-11-21 | 2026-02-03 | 케이스 웨스턴 리저브 유니버시티 | 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법 |
| JP2021134242A (ja) | 2020-02-25 | 2021-09-13 | 株式会社アイティー技研 | 鉱物油精製方法及び装置 |
| JP7574640B2 (ja) | 2020-12-23 | 2024-10-29 | 株式会社リコー | 画像処理装置、画像処理システム、方法およびプログラム |
-
2018
- 2018-04-09 WO PCT/US2018/026739 patent/WO2018187810A1/en not_active Ceased
- 2018-04-09 AU AU2018249956A patent/AU2018249956B2/en active Active
- 2018-04-09 JP JP2019554986A patent/JP7178360B2/ja active Active
- 2018-04-09 US US16/603,544 patent/US11426420B2/en active Active
- 2018-04-09 CN CN201880028200.4A patent/CN110891568A/zh active Pending
- 2018-04-09 CA CA3059255A patent/CA3059255A1/en active Pending
- 2018-04-09 EP EP18781322.5A patent/EP3606520A4/en active Pending
-
2022
- 2022-07-27 JP JP2022119729A patent/JP2022141930A/ja active Pending
- 2022-08-23 US US17/893,777 patent/US20230165883A1/en not_active Abandoned
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
| US12616681B2 (en) | 2022-08-22 | 2026-05-05 | Case Western Reserve University | Compositions and methods for treating renal injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516617A5 (https=) | ||
| JP2020510054A5 (https=) | ||
| RU2016142704A (ru) | Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR | |
| RU2013141829A (ru) | Цитотоксические производные бензодиазепина | |
| KR101230085B1 (ko) | ７―(２,５-디히드로―４-이미다조［１,２-ａ］피리딘-３-일-２,５-디옥소-１ｈ-피롤-３-일)-９-플루오로-１,２,３,４-테트라히드로-２-(１-피페리디닐카르보닐)-피롤로［３,２,１-ｊｋ］［１,４］벤조디아제핀에 의한 암 화학요법의 강화 | |
| JP2009515890A5 (https=) | ||
| RU2011103434A (ru) | Изоиндолоны и способы их применения | |
| JP2006036796A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2010511626A5 (https=) | ||
| RU2006138040A (ru) | Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ | |
| JP2018511616A5 (https=) | ||
| JP2021508697A5 (https=) | ||
| RU2010121763A (ru) | Производные пиридазинона и ингибиторы р2х7 рецептора | |
| RU2011136686A (ru) | Новые производные бензодиазепина | |
| JP2009524591A5 (https=) | ||
| JP2011509260A5 (https=) | ||
| AU2016279051A1 (en) | Delivery systems for controlled drug release | |
| JP2018527292A5 (https=) | ||
| JP2009541225A5 (https=) | ||
| JP2008520719A5 (https=) | ||
| JP2009511599A5 (https=) | ||
| US11634405B2 (en) | Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties | |
| CA2260060C (en) | Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | |
| MX2024010782A (es) | Agentes ligadores de fenil maleimida |